Since our founding in May 1998 we have been focused on the impact of cortisol and the potential benefits of developing glucocorticoid receptor antagonists. About 80 percent of the tissues in the body have receptors for cortisol, and the effects of excess cortisol are severe and often life-threatening.


Publications show all

Corcept Therapeutics has published 39 articles.

Patents show all


Clinical Trials show all

10Phase 39Phase 15Phase 22Phase 1/Phase 2

SEC Filings show all


Contact Information

149 Commonwealth Drive
Menlo Park, CA 94025
United States



    Total FundingEmployeesLast Funding DateStatus

    Crunchbase Investment Rounds

    DateAmountRoundValuationLead InvestorOther Investors
    2001-05-01$28,000,000Series Unknown$113,000,000
    2006-11-15$3,000,000Series Unknown
    2002-12-01$12,800,000Series Unknown$125,000,000
    2010-04-30$7,651,215Post Ipo Equity
    2009-10-30$18,012,959Post Ipo EquityAlta Partners, Longitude Capital, Sutter Hill Ventures
    2007-08-20$10,100,000Post Ipo EquityPaperboy VenturesAlta Partners, Sutter Hill Ventures
    2012-04-10$525,305Post Ipo Equity